CyPath® Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing revenue increases 79% year-to-date
Company advances precision medicine pipeline with
Benefits of CyPath® Lung to be shared with North Carolina patient advocacy and healthcare community at November 5 "Battle of the Blues" EventIn recognition of National Lung Cancer Awareness Month, bioAffinity
Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung
Presentation to address current challenges in pulmonary nodule management and to discuss preliminary
Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targets
Company advances research and development in diagnostic tests for major lung
JERSEY CITY, N.J., Oct. 9, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has closed its
JERSEY CITY, N.J., Oct. 8, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has entered into
Company’s expanding intellectual property portfolio strengthens protection for its early lung cancer diagnostic in Asia
Patent strategy protects proprietary CyPath Lung flow cytometry+AI approach in international
Nearly 90% increase in number of physician offices using CyPath Lung
Utilization expands as physicians who ordered CyPath Lung in 2025 increase usage by nearly 50%
bioAffinity Technologies, Inc. (NASDAQ:BIAF,
Companies debut federal distribution collaboration to VA leadership, administrators and physicians at NAVREF 2026bioAffinity engages GO2 for Lung Cancer network to broaden outreach to veterans at riskbioAffinity
Presentations demonstrate beneficial role for CyPath Lung in veteran lung cancer care
NAVREF 2026 focuses on innovative research to improve healthcare for veterans
bioAffinity Technologies, Inc. (NASDAQ:BIAF,
DENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The small-cap market is delivering a mix of catalysts, with the following companies in particular putting substantial new developments in front of investors: Aethlon Medical
Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian market
Asia accounts for nearly two-thirds of lung cancer cases worldwide
bioAffinity Technologies, Inc.
DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies
